Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Bilirubin-Induced Neurologic Damage - Mechanisms and Management Approaches
NEJM 369:2021-2030, Watchko, J.F.,et al, 2013
Cluster Headache
BMJ 344:e2407, Nesbitt,A.D.,et al, 2012
Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
Effects of a Central Cholinesterase Inhibitor on Reducing Falls in Parkinson Disease
Neurol 75:1263-1269, Chung,K.A.,et al, 2010
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Association of Olfactory Dysfunction With Risk for Future Parkinsons Disease
Ann Neurol 63:167-173,132, Ross,G.W.,et al, 2008
Nonsteroidal Anti-Inflammatory Drugs and the Incidence of Parkinson Disease
Neurol 66:1097-1099, Hernan,M.A.,et al, 2006
Neurologic Manifestations and Outcome of West Nile Virus Infection
JAMA 290:511-515,524,558, Sejvar,J.J.,et al, 2003
Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease
Arch Neurol 60:1059-1064,1043, Chen,H.,et al, 2003
A Meta-Analysis of Coffee Drinking, Cigarette Smoking, and the Risk of Parkinson's Disease
Ann Neurol 52:276-284,261, Hernan,M.A.,et al, 2002
Association of Coffee and Caffeine Intake With the Risk of Parkinson Disease
JAMA 283:2674-2679, Ross,G.W.,et al, 2000
Postmenopausal Estrogen Use and Parkinson's Disease with and without Dementia
Neurol 50:1141-1143, Marder,K.,et al, 1998
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
NEJM 336:1216-1222, 12451997., Sano,M.,et al, 1997
Dietary Antioxidants and Parkinson Disease
Arch Neurol 54:762-765, deRijk,M.C.,et al, 1997
Case-Control Study of Idiopathic Parkinson's Disease and Dietary Vitamin E Intake
Neurol 46:1270-1274, Morens,D.M.,et al, 1996
Cigarette Smoking and Protection from Parkinson's Disease:False Association or Etiologic Clue?
Neurol 45:1041-1051, Morens,D.M.,et al, 1995
Comparison of Therapeutic Effects & Mortality Data of Levodopa & Levodopa with Selegiline in Pts with Early, Mild Parkinson's
BMJ 311:1602-1607, 15831995., Lee,A.J.,et al, 1995
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994